The burden of disease due to influenza B is often underestimated. Clinical studies have shown that oseltamivir, a widely used neuraminidase inhibitor (NAI) antiviral drug, may have reduced effectiveness against influenza B viruses. Therefore, it is important to study the effect of neuraminidase mutations in influenza B viruses that may further reduce NAI susceptibility, and to determine whether these mutations have the same effect in the two lineages of influenza B viruses that are currently circulating (B/Yamagata-like and B/Victoria-like).
Introduction
Annual influenza outbreaks are a major threat to public health, causing significant morbidity and mortality. 1 Influenza A viruses are generally associated with considerable disease burden, but accumulated evidence from epidemiological studies indicates that influenza B viruses also cause substantial disease, especially in children. 2 Influenza B viruses formed a homogenous group until the 1970s, after which they diverged into two antigenically and genetically distinct lineages, B/Victoria/2/87-like (B/Victoria) and B/Yamagata/16/88-like (B/Yamagata), that now co-circulate globally. 3, 4 Antivirals are primarily used for the treatment of influenza infection in severely ill patients, and also have an important role in prophylaxis during outbreaks, particularly in closed settings such as nursing homes. 5 -7 The neuraminidase inhibitors (NAIs) are a class of antivirals that act by blocking the viral neuraminidase (NA), thereby preventing the release of virus from infected cells. Oseltamivir and zanamivir are the most commonly used NAIs and have been licensed in many countries since 2000. 8, 9 More recently, two new long-acting inhibitors, laninamivir and peramivir, have been licensed for use in selected countries such as Japan. 9 A number of studies assessing oseltamivir treatment versus placebo or the effect of oseltamivir treatment in influenza A versus influenza B-infected patients found that oseltamivir may have a lower clinical efficacy against influenza B viruses than against influenza A viruses. 10 -18 In vitro analyses have also demonstrated that the oseltamivir IC 50 (the concentration of drug required to inhibit NA activity by 50%) of circulating viruses is substantially higher for influenza B viruses than for influenza A viruses). 9,19 -24 Mutations in the NA that affect NAI binding can further increase the IC 50 values in both influenza A and B viruses. The most commonly observed NA mutation that alters oseltamivir susceptibility in influenza A (H1N1) viruses is the H275Y NA mutation. 24 Oseltamivir-resistant seasonal A (H1N1) viruses with the H275Y NA mutation circulated globally during 2008 and early 2009, demonstrating the ability of a resistant virus to transmit and spread widely amongst the community. 24 -26 Given that commonly circulating influenza B viruses already have reduced susceptibility to oseltamivir compared with influenza A viruses, there is concern that any further increases in IC 50 due to NA mutations may lead to complete loss of drug effectiveness for influenza B treatment or prophylaxis.
To date, surveillance and in vitro studies have reported various NA mutations in influenza B viruses that can reduce NAI susceptibility. 13,19,22,24,27 -46 The most commonly detected NA mutations have occurred in framework residues [positions 117, 197, 221, 273 and 294 (influenza B NA numbering starting at first methionine)], which provide structural support to the NA active site, rather than in catalytic residues, which have a direct role in drug/substrate binding. Several studies in influenza A and B viruses have found that, while mutations in the catalytic sites typically have a negative effect on virus replication and function, those in framework residues have less effect on function and viral fitness. 27 -30 In addition, a small number of studies have identified mutations in residues located at the NA monomeric interface of influenza B viruses (residues 105, 138, 139 and 140) that also alter NAI susceptibility. 31, 32 Because many of these mutations have been detected in different influenza B viruses and analysed in various laboratories using different assays (sometimes only determining oseltamivir and zanamivir susceptibility), a direct comparison of the effect and relevance of these framework and monomeric interface mutations is currently difficult. In addition, many of these mutations have only been reported in influenza B viruses from one B-lineage, meaning that knowledge of how a mutation affects the NAI susceptibility of the viruses from the other B-lineage is unknown. Using public sequence databases we investigated the frequency of mutations at residues previously reported to alter NAI susceptibility (framework residues 117, 197, 221, 273, 294 and monomeric interface residues 105, 138, 139, 140) in either B/Yamagata or B/Victoria lineage viruses and then, using reverse genetics (RG) and functional assays, determined the effect of each mutation on NA activity and NAI susceptibility of viruses that had contemporary B/Yamagata and B/Victoria NAs. 
Materials and methods

Cells
Preparation of RG plasmids
Eight pAD3000 plasmids containing each of the gene segments of B/Yamanashi/166/98 virus (a B/Yamagata lineage virus) were kindly provided by Dr Kemble, Med Immune, USA. In addition, NA gene segments from a contemporary B/Yamagata virus (B/South Australia/4/2013) and a B/Victoria virus (B/Townsville/1/2013) were amplified using the SuperScript w One-Step RT-PCR System for Long Templates (Life Technologies, USA) and inserted into empty pAD3000 plasmids. RG viruses were generated as 1+7 reassortments containing a contemporary NA gene and the remaining segments from B/Yamanashi/166/98.
Site-directed mutagenesis (Gene Art w Site-Directed Mutagenesis Kit, Life Technologies, USA) was used to introduce specific NA mutations into the contemporary NA plasmids. The NA substitutions chosen for our analysis were based on previous surveillance and research papers reporting mutations that significantly altered the NAI susceptibility of influenza B viruses. These were mutations of framework residues E117A, E117G, D197N, D197E, I221T, I221V, I221L, H273Y and N294S, and mutations of NA monomeric interface residues E105K, Q138R, P139S and G140R ( Figure 1) . 8,13,19,24,31 -51 In addition, interrogation of these residue positions 105, 117, 138, 139, 140, 197, 221, 273 and 294 in the public sequence databases (GISAID and GenBank) revealed three other substitutions I221N, Q138K and H273N, which although not previously reported to alter NAI susceptibility, were also included in our study.
Generation of influenza B viruses with NA mutations
Viruses were generated using an RG method adapted from Hoffmann et al. 52 Cos 7 and MDCK cells were transiently co-cultured in a 3: 1 ratio and seeded at a concentration of 2×10 5 cells/mL in Opti-Mem w growth media, 24 h prior to transfection. A 1 mg aliquot of viral DNA was incubated for 45 min with transfection media (GibcoOpti-Mem w +GlutaMax with 200 U/mL penicillin, 200 mg/mL streptomycin and 2 nM L-glutamine) and GeneJuice w Transfection reagent (Merck Millipore, USA). Co-cultured cells were incubated with 1 mL of transfection mixture at 358C, 5% CO 2 for 6 h. The transfection mixture was then removed and replaced with 1 mL of fresh transfection media supplemented with TPCK-trypsin (2 mg/mL; SAFC Biosciences, USA). The transfected cells were incubated at 358C, 5% CO 2 . After 2 -6 days (post-transfection) supernatant from the co-culture was used to infect MDCK cells. Viral replication in MDCK cell supernatant was determined using a haemagglutination assay and 1% (v/v) turkey red blood cells. 53 
NA activity assay
To determine the NA activity, viruses were standardized to 4 haemagglutination units using 1% (v/v) turkey red blood cells, 53 serially diluted 2-fold and 50 mL was incubated with 50 mL of 0.3 mM 2 ′ -(4-methylumbelliferyl)-a-D-N-acetlyneuraminic acid (MUNANA; Sigma-Aldrich, USA) at 378C for 1 h. A 100 mL aliquot of stop solution (0.1 6 M NaOH in absolute ethanol) was added to terminate the reaction and the fluorescence of the enzymatic product released by viral NA, 4-methylumbelliferone, was measured using a Fluoroscan II Fluorometer (Labsystems, Australia) with an excitation wavelength of 355 nm at slit width 2.5 nm and emission wavelength of 460 nm at slit width 2.0 nm. The assay was performed in triplicate. After subtraction of background fluorescence of the buffer alone, the NA activity of the WT viruses at each dilution was plotted. The virus dilutions that corresponded to the linear section of the activity curve were noted and, using the data only from those dilutions, the NA activity of the RG viruses was calculated as a percentage of the mean NA activity of the corresponding WT virus. When standardizing viruses on haemagglutination titre there is an Antiviral susceptibility of influenza B viruses 2005 JAC assumption that the levels of NA incorporated into the virion and the ratio of haemagglutination titre to NA protein are similar for all RG viruses.
NAI susceptibility assays
A fluorescence-based NA inhibition assay was used to determine IC 50 values as described previously. 34 Briefly, viruses were incubated with varying concentrations of oseltamivir carboxylate, zanamivir, laninamivir and peramivir (kindly provided by Hoffmann-La Roche Ltd, Switzerland; GlaxoSmithKline, Australia; Daiichi-Sankyo, Japan; and BioCryst Pharmaceuticals, USA, respectively) for 45 min at room temperature. MUNANA (0.3 mM) (Sigma-Aldrich, USA) was then added to the mixture, which was further incubated at 378C for 60 min. A 100 mL aliquot of stop solution (0.16 M NaOH in absolute ethanol) was added to terminate the reaction. The fluorescence of the enzymatic product released by viral NA activity was measured using the Fluoroscan II Fluorometer (Labsystems, Australia) with an excitation wavelength of 355 nm at slit width 2.5 nm and emission wavelength of 460 nm at slit width 2.0 nm. The IC 50 of viruses was determined by the curve fitting program Jaspr (kindly provided by the CDC, USA).
Criteria established by the WHO Influenza Antiviral Working Group were used to describe the NAI susceptibility of influenza B viruses. Viruses were described as having 'normal inhibition', 'reduced inhibition' (RI) (where viruses have a 5-50-fold higher IC 50 than a relevant reference virus with normal inhibition) or 'highly reduced inhibition' (HRI) (where viruses have a .50-fold higher IC 50 than a relevant reference virus with normal inhibition). 46 
Results
Frequency of NA mutations in recently circulating viruses
To determine the frequency of NA mutations, all publicly available influenza B NA sequences on GISAID/GenBank were analysed (as of 28 October 2014). A total of 69 sequences were detected with mutations in the nominated framework residues (Figure 1 ), of which 35 (0.79%) were in B/Yamagata viruses and 34 (0.67%) were in B/Victoria viruses (Table 1 ). Substitutions at the framework residue I221, particularly I221T (n¼ 11) and I221V (n¼ 16), were the most frequently detected of the nominated framework mutations. I221T was detected predominantly in B/Yamagata viruses (10/11 sequences), whilst I221V, I221L and I221N were almost exclusively detected in B/Victoria viruses (20/21 sequences) ( Table 1 ). Mutations at residue D197 were the second most commonly detected, seen almost exclusively in B/Yamagata viruses ( Table 1 ). The H273Y NA mutation, the third most commonly detected framework substitution, has been detected in both B/Yamagata viruses (n ¼ 3) and B/Victoria viruses (n ¼ 8). Across the five nominated monomeric interface residues (Figure 1 ), 19 sequences contained mutations with the majority (n ¼14) occurring in B/Victoria viruses. E105K and G140R were the two most commonly detected substitutions, with both occurring more frequently in B/Victoria viruses than B/Yamagata viruses (Table 1) .
NA activity of experimentally generated influenza B variants
Following mutagenesis of B/Yamagata and B/Victoria NAs to introduce the NA substitutions of interest, the RG variants were investigated in various functional assays. All mutations resulted in reduced NA activity, but in general, a larger reduction in NA activity was observed in the B/Yamagata NAs compared with the B/Victoria NAs. Irrespective of lineage type, all of the monomeric interface mutations caused very large reductions in NA activity, Farrukee et al.
retaining only 4% to 31% of the activity observed in the WT virus ( Figure 2 ). In comparison, the framework mutations retained 23% -74% of NA activity, with the exception of mutations of the E117 residue, which had only 1%-8% activity compared with the WT virus (Figure 2 ).
NAI susceptibility of influenza B variants
Framework mutations
A total of 11 NA framework mutations were studied, of which five (E117A, E117G, I221N, I221L and H273Y) caused HRI to at least Of the four substitutions at residue I221, viruses with the I221N and I222L mutations showed HRI or RI to oseltamivir and peramivir and RI to zanamivir, whereas substitutions I221T or I221V had less effect ( Table 2 ). The H273Y mutation, equivalent to the H275Y mutation commonly observed in seasonal H1N1 or H1N1pdm09 influenza A viruses, caused HRI to peramivir ( 70-fold increase in IC 50 ) and a 4 -8-fold increase in oseltamivir IC 50 . In comparison, the H273N mutation retained susceptibility to all four NAI drugs in both lineages. Mutations at N294S and D197E caused RI to oseltamivir and peramivir, while D197N led only to RI to oseltamivir in the B/Victoria NA ( Table 2) .
Monomeric interface mutations
Five mutations at the monomeric interface were studied and all were found to lead to varying levels of reduced inhibition to the drugs tested (Table 3) . Mutations P139S, G140R and E105K caused RI or HRI to all four drugs tested in either the B/Victoria or B/ Yamagata NAs, or both. In comparison, substitutions Q138K and Q138R only altered peramivir susceptibility, causing 16 -91-fold increases in IC 50 .
Comparison of the effect of mutations in B/Yamagata or B/Victoria NAs
The effect of substitutions of framework and monomeric interface residues in either the B/Yamagata or B/Victoria NA was compared and the fold differences between IC 50 values of the NAs from the two lineages were calculated. The IC 50 for the WT B/Victoria-like NA was 1.1 -2.7-fold higher than that of the B/Yamagata-like NA, depending on the NAI being used, which may partially explain the higher IC 50 values typically seen for the mutants in the B/Victorialike NA. In most cases the IC 50 values for B/Yamagata-like and B/Victoria-like NAs with framework mutations were within 3-fold of each other (Figure 3 ). Of the framework mutations, the I221L mutation produced the most marked difference between the lineages across all four NAIs (3.1-5.8-fold higher IC 50 for the B/Victoria-like NA). For the substitutions E117A and E117G, oseltamivir IC 50 values were consistently higher in the B/Yamagata NA, but laninamivir IC 50 values were higher when the mutations were introduced in the B/Victoria NA. However, across all framework NA mutations the maximum fold difference between NAs of the two lineages did not exceed 9-fold.
In comparison, the effect of mutations at the monomeric interface differed considerably depending on whether they occurred in a B/Victoria-or B/Yamagata-like NA. Substitutions P139S and G140R caused peramivir IC 50 values that were at least 1000-fold higher in the B/Victoria NA than in the B/Yamagata (2) 4.2+0.9 (2)** Mean IC 50 and standard deviations are based on five independent assays of the same stock tested on separate days by multiple operators. Viruses classified as having reduced inhibition are shaded in light grey and those with highly reduced inhibition are indicated by dark grey shading. A Mann-Whitney U non-parametric test to determine whether the mean IC 50 value of the variant virus was significantly higher than that of the WT virus was conducted where *P value was ,0.05 and **P value was ,0.01. '-' indicates that the virus with this mutation could not be generated. ' †' indicates the presence of a mixed viral population containing both WT and mutated viruses.
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NA (Figure 3) . The same mutations also caused significantly higher zanamivir and laninamivir IC 50 values (between 100-and 1000-fold) in the B/Victoria NA, resulting in viruses that had much higher zanamivir, laninamivir and peramivir IC 50 values than oseltamivir IC 50 values The E105K mutation also produced different IC 50 values depending on the B lineage, with the zanamivir and peramivir IC 50 values being 32-and 120-fold higher in the B/Victoria NA ( Figure 3) . Mutations Q138K and Q138R behaved similarly in both backgrounds, with no effect on zanamivir, oseltamivir or laninamivir susceptibility, but conferring either highly reduced or reduced inhibition to peramivir (Table 3) .
Discussion
This study aimed to investigate the effect of mutations of framework and monomeric interface residues of the influenza B viral NA on NAI susceptibility. In addition, we investigated whether key NA substitutions caused a differential effect in either a B/Yamagata or B/Victoria NA. Our results indicate that three substitutions in the monomeric interface (E105K, P139S and G140R) caused substantially higher IC 50 values in a B/Victoria NA compared with the temporally equivalent B/Yamagata NA. In addition, many of the other substitutions also caused greater IC 50 values in the B/Victoria NA than in the B/Yamagata NA, although the effect was typically ,10-fold, and, therefore, may be due to an inherent difference in the susceptibility of the WT viruses from the two lineages. A study of influenza B viruses from Portugal in 2011 -12 found that oseltamivir and zanamivir median IC 50 values were higher for B/Victoria lineage viruses than for B/Yamagata lineage viruses, although statistical analysis was not possible due to the small numbers tested. 54 A worldwide surveillance study in 2011 also found that mean oseltamivir IC 50 values for B/Victoria viruses were 2-fold higher than B/Yamagata viruses, but the mean zanamivir IC 50 for B/Victoria viruses (1.23 nM) was lower than for B/Yamagata viruses (1.86 nM). 50 Analysis of surveillance data from our laboratory also shows that in the years 2010, 2012 and 2013, B/Victoria-like viruses had higher median oseltamivir IC 50 than B/Yamagata-like viruses (data not shown).
Analysis of influenza B NA sequence data from public databases showed a clear trend for certain mutations to occur more frequently in one influenza B lineage. This has been observed with influenza A subtypes, where certain NA mutations occur predominantly in one NA subtype and rarely, or not at all, in other subtypes, suggesting that the mutation has different effects on viral fitness depending on the NA or other genes of the virus. For example, the H275Y mutation is frequently detected in circulating viruses with an N1 NA, but is not detected in N2-containing viruses, while E119V is readily detected in oseltamivir-treated patients infected with A(H3N2), but not A(H1N1) viruses. 55, 56 Three mutations (I221N, Q138K and H273N) were included in this study because they occurred at residues that are known to influence NAI susceptibility, but their effect had not been previously described. The H273N mutation had no effect on NAI susceptibility, even though H273Y in influenza B NA causes highly reduced peramivir inhibition, and Q138K caused reduced inhibition to peramivir, but had no effect on susceptibility to the other NAIs. The I221N mutation was shown to confer highly reduced inhibition to oseltamivir and peramivir and reduced inhibition to zanamivir, resulting in IC 50 values that were typically Table 3 . NAI susceptibility of viruses with mutations in residues of the monomeric interface are shaded in light grey and those with highly reduced inhibition are indicated by dark grey shading. A Mann-Whitney U non-parametric test to determine whether the mean IC 50 value of the variant virus was significantly higher than that of the WT virus was conducted where *P value was ,0.05 and **P value was ,0.01. '-' indicates that the virus with this mutation could not be generated. Mutations at the NA monomer interface that reduce drug susceptibility of virus have only recently been reported and the mechanism by which they affect NAI binding is not well understood. 31, 32 It is hypothesized that mutations in this region cause long-range conformational changes in the overall tertiary structure of the NA protein, which affect drug-binding interactions. 31, 32 However the NA activity data suggest that mutations in the NA monomeric interface may be more disruptive to structural stability than changes in the framework residues, potentially producing viruses that do not replicate or transmit efficiently. Although cell culture virus isolates containing mutations E105K, Q138R and G140R have been reported, analysis of the associated patient clinical specimens found that mutations were present at undetectable levels (,1% of viral population), or in the case of viruses with the P139S mutation, were present as a low proportion (2.7%) of the viral population. 31, 32 This further suggests that viruses with NA monomeric interface mutations may have low viral fitness, although transmission and replication studies in animal models are required to confirm this theory.
The results of this study suggest that several new factors need to be taken into consideration for surveillance and research studies on antiviral susceptibility of influenza B viruses. The presence of mutations of monomeric interface residues underscores the importance of screening sites other than the NA active site for possible resistance conferring mutations. In addition, the frequency of key NA mutations, and the effect that they have on NA activity and NAI susceptibility, can differ between the two influenza B lineages. However, because a number of reassortant viruses that contain a B/Yamagata-like HA gene and B/Victorialike NA gene have been detected in recent years, it is important that future studies comparing the IC 50 values of the two lineages confirm the NA lineage and do not assume that it is the same lineage as the haemagglutinin gene. The two influenza B lineages are believed to be evolutionarily competitive and continue to diverge due to differential genetic/selection pressures. 3 Therefore, continued surveillance and analysis is important if one lineage develops a higher propensity for developing resistance than another, such as that currently seen with N1-compared with N2-containing influenza A viruses. 
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